Ablynx nabs €5M as Boehringer Ingelheim chooses first Nanobody for pre-clinic
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim is to pay Ablynx a €5 million milestone, having selected the first Nanobody to enter preclinical development from the deal that the two companies signed in September 2007.